Status:
COMPLETED
A Study of Taspoglutide in Type 2 Diabetic Patients
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This crossover study will assess the effect of 2 doses of Taspoglutide on first- and second-phase insulin secretion in patients with type 2 diabetes. Patients will receive a continuous subcutaneous in...
Eligibility Criteria
Inclusion
- adult patients, 18-65 years of age;
- type 2 diabetes mellitus;
- treated with diet and exercise alone, or in combination with stable metformin for at least 3 months prior to screening.
Exclusion
- type 1 diabetes mellitus;
- type 2 diabetes duration of \<3 months;
- treatment with any oral anti-hyperglycemic medication other than metformin monotherapy during last 3 months;
- treatment with insulin for \>7 days within 6 months prior to screening.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00811460
Start Date
November 1 2008
End Date
August 1 2009
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuss, Germany, 41460